Company / Depreciation & Amortization
Bio-Rad Laboratories Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$165.4M
FY2025
5-year range
$137.3M / $165.4M
FY2021-FY2025
Trend
+9.1%
vs FY2024
Sector context
#48 of 141
Health Care
What the data says
At $165M, Bio-Rad Laboratories's depreciation & amortization ranks #94 of 141 in the Health Care sector. Depreciation & Amortization has increased for 3 consecutive years, from $137M in FY2022 to $165M in FY2025.
Based on SEC 10-K filings.
$165M in FY2025 with a 5-year CAGR of +3.7%.
Increased from $146M to $165M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Sector benchmark
#94 of 141 in Health CareTop 66% of 141This company $165.4M Sector average $344.6M
▼
-52.0% below sector average
Key checks
Key Insights
- Bio-Rad Laboratories's depreciation & amortization has grown for 3 consecutive years.
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 9.1% year-over-year.
- Ranks #48 out of 141 companies in the Health Care sector.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $165.4M | +9.1% |
| FY2024 | $151.6M | +3.9% |
| FY2023 | $145.9M | +6.3% |
| FY2022 | $137.3M | -0.2% |
| FY2021 | $137.6M | -0.4% |
| FY2020 | $138.1M | +2.9% |
| FY2019 | $134.2M | -6.1% |
| FY2018 | $142.9M | +8.4% |
| FY2017 | $131.8M | -12.1% |
| FY2016 | $149.9M | +13.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026